Video: Long-Term GA Data Support Early Treatment

At ASRS 2025, Roger Goldberg, MD, presented 48-month results from OAKS, DERBY, and GALE. He discussed the findings with Diana Do, MD.

By: Roger A. Goldberg, MD, MBA, Diana V. Do, MD

Retinal Physician August 3, 2025 Vol 22, Issue July/August 2025

Clinical Report: Long-Term GA Data Support Early Treatment

Overview

Recent findings from the 48-month data on pegcetacoplan indicate significant preservation of retinal tissue in patients with geographic atrophy (GA) when treated continuously. The data suggest that earlier intervention may enhance functional outcomes and reduce the risk of scotoma development.

Background

Geographic atrophy is a progressive condition associated with age-related macular degeneration, leading to irreversible vision loss. Early treatment is crucial as it may slow disease progression and preserve visual function. The introduction of complement inhibitors like pegcetacoplan represents a significant advancement in managing GA.

Data Highlights

{'Tissue Preservation (4 years)': '1.5 disc areas (monthly treatment arm)', 'GA Growth Reduction (2nd 2 years)': '10% to 15% further reduction in GA growth', 'Tissue Preservation in Crossed-Over Patients': '1.1 mm² vs. almost triple in 4-year treatment', 'Risk Reduction on Microperimetry': 'One-third risk reduction in critical loci', 'Safety Profile': 'No new safety signals observed; consistent with previous studies'}

Key Findings

4-year continuous treatment with pegcetacoplan preserves significant retinal tissue.
Patients on longer-duration therapy show increasing efficacy in reducing GA growth.
Crossed-over patients exhibited less tissue preservation compared to those on continuous treatment.
Functional benefits on microperimetry indicate a reduced risk of developing scotomas.
No new safety concerns were identified in the long-term treatment data.

Clinical Implications

The findings underscore the importance of initiating treatment for geographic atrophy as early as possible to maximize tissue preservation and functional outcomes. Clinicians should consider the long-term benefits of pegcetacoplan therapy when discussing treatment options with patients.

Conclusion

The long-term data on pegcetacoplan reinforce the need for early intervention in geographic atrophy, highlighting both tissue preservation and functional benefits. Continued monitoring of safety and efficacy will be essential as treatment protocols evolve.

PentaVision

Retinal Physician